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ABSTRACT  
Rationale: Longitudinal, population-based studies can better assess the relationship of 
ecstasy use with depression. 
Objectives: We examined whether change in ecstasy use was associated with change in 
depressive symptoms/probable depression over a 4 year period, among a large Australian 
sample.  
Methods: The Personality and Total Health (PATH) project is a longitudinal general 
community study of Australians from Canberra and Queanbeyan. Data from the youngest 
cohort when aged 24-30 (N = 2, 128) and 4 years later (N = 1, 977) was included. The 
Goldberg depression scale and the Brief Patient Health Questionnaire measured 







also considered demographics, psychosocial characteristics and other drug use. 
Results: Ecstasy use was not associated with long-term depressive symptoms or greater 
odds of depression. Users had more self-reported depressive symptoms when using 
ecstasy compared to not using. However, differences between people who had and had 
not ever used ecstasy largely accounted for this. Other factors were more important in the 
prediction of depression. 
Conclusions: It would be premature to conclude that ecstasy use is not related to the 
development of long-term depressive symptoms, given the relatively low level of ecstasy 
and other drug use in this community sample. Results showed that other factors need to 
be considered when investigating ecstasy use and depression.  
Keywords: ecstasy, 3,4-Methylenedioxymethamphetamine (MDMA), depression, mental health, general 
community sample. 
INTRODUCTION 
 Despite recent decreases in ecstasy use in Australia (Australian Institute of Health 
and Welfare 2011), the Oceanic region continues to have the highest annual prevalence of 
the drug (United Nations Office on Drugs and Crime 2012). Use of 
3,4-Methylenedioxymethamphetamine (MDMA) has been associated with damage to the 
serotonin (5-HT) system in animals (e.g. Mueller et al. 2012) and humans (e.g. Buchert et 
al. 2004). Unsurprisingly many studies have investigated depression among ecstasy users, 
with residual symptoms reported (e.g. Curran et al. 2004; Curran and Travill 1997) as 
well as greater symptoms relative to drug naive and/or polydrug controls (e.g. Morgan et 
al. 2002; Roiser and Sahakian 2004). However, not all studies have found an effect of 
ecstasy use with depression symptoms (e.g. Scott et al. 2010; Thomasius et al. 2006). 
Inconsistencies may reflect the heterogeneity of research methodologies which make it 
difficult to draw conclusions (Guillot 2007; Rogers et al. 2009).   
 To date, limitations in the literature have included reliance upon small snowball 
samples and knowledge of study aims among participants. Additionally, as most ecstasy 







effects reflect the acute/residual pharmacological effects of other drugs, particularly 
cannabis, is also an ongoing issue. Some investigations have determined that poorer 
mental health among ecstasy users is associated more with other drugs (e.g. Daumann et 
al. 2004; Durdle et al. 2008; Medina and Shear 2007) with a limited number of studies 
reporting higher scores among ecstasy users, relative to polydrug controls (see Guillot 
2007).  
 Another issue is the possibility of a somatic symptom bias among ecstasy users 
(Bedi et al. 2010; Sumnall and Cole 2005). George, Windsor and Rogers (2011) found no 
specific item endorsement bias among ecstasy users on a measure of psychological 
distress, consistent with Roiser and Sahakian (2004) where somatic depression symptoms 
were examined among ecstasy users relative to controls. Although, Bedi and colleagues 
(2010) found differences for somatic anxiety symptoms. Multiple assessments of 
symptoms may help to address this potential concern. 
 In addition, there remains a paucity of longitudinal investigations meaning that 
cause and effect associations cannot be inferred (Rogers et al. 2009). Of the limited 
studies, some found no evidence for increased depressive symptoms among ecstasy users 
(Daumann et al. 2004; Thomasius et al. 2006) including a prospective study of incident 
users over 2 years (de Win et al. 2007). More recently, a decline in BDI scores over 2 
years among both current and former ecstasy users was noted among a larger sample 
(Falck et al. 2008). Results for mood disorders are also mixed—Martin-Santos et al. 
(2010) found that ecstasy users had a higher incidence of primary mood disorder over 3 
years compared with drug naive and cannabis controls, but Lieb et al. (2002) found mood 
disorders were more likely to precede, rather than follow, ecstasy/amphetamine use. 
Again, studies have been subject to methodological issues with most relying on small 
samples and, limited follow up.  
 Some potential confounds remain unexplored longitudinally in the ecstasy and 
depression literature. Recent research highlights the importance of considering 
demographic and psychosocial characteristics, in addition to other drug use. George et al. 
(2010) found that ecstasy use was not independently associated with psychological 







were more important. Scott et al. (2010) reported no relationship of lifetime or recent 
ecstasy use with mood, but stressful life events, lifetime trauma and other drug use 
emerged as significant predictors. These studies were cross-sectional and thus 
consideration of the influence of such factors in a longitudinal investigation of ecstasy 
use with mental health is needed. 
 The current study aimed to address several issues within the literature. First, the 
association of ecstasy use with depression was examined among a large Australian 
general community, rather than a small purposive sample. Second, participants were 
followed over 4 years. Third, measures of both symptoms and indicators of major 
depression were used. Next, the study included measures of psychosocial characteristics, 
such as lifetime trauma and social support meaning that these potential confounds could 
also be considered. Finally, given the epidemiological nature of the study design, the 
focus of the current study regarding ecstasy use was not known to participants and 
interviewers were blind to ecstasy use status. The specific research questions were as 
follows: 
1. Is a change in ecstasy status (use/non-use) associated with changes in 
self-reported depressive symptoms and probable depression over a 4 year 
period? 
2. Does any effect of ecstasy use hold with consideration for demographics, 
psychosocial characteristics and use of other drugs? 
METHOD 
Participants 
 Participants were from the Personality and Total Health (PATH) Through Life 
Project, a longitudinal investigation which aims to re-interview three age cohorts (20-24, 
40-44 and 60-64 years) every 4 years for 20 years. Originally, participants were randomly 







Australia. Enrolment to vote is compulsory for Australian citizens aged 18 years and over 
with very rare exceptions. At Wave 1, there was a 58.6% response rate for the youngest 
cohort among those who were contactable.  
 The current investigation includes data from the youngest cohort at Waves 2 and 3 
when ecstasy items were included in PATH and participants were aged 24-30 years and 
28-34 years, respectively.  Of the 2,404 younger participants who completed Wave 1 
interviews, 2,139 completed Wave 2 (89% retention) and 1,978 completed Wave 3 (82% 
retention).  A total of 2,128 participants provided ecstasy use data at Wave 2 and 1,977 
participants at Wave 3 and were included in the current study.  
Procedure 
 At Wave 2, Participants completed a questionnaire using a hand-held computer, 
with a trained interviewer in the room to answer any questions. The advantage of 
increased confidentiality among respondents was noted in a review of web-based surveys 
for illicit drug use research (Miller and Sønderlund 2010). At Wave 3, participants 
completed the study via an online survey. This study was approved by the Australian 
National University Human Research Ethics Committee. 
Questionnaire 
Ecstasy use 
 At both waves, participants were asked questions regarding lifetime use of ecstasy 
(ever used ecstasy [pills, E, eccy, XTC and MDMA]) and use in the past year. If they had 
used the drug in the prior 12 months they were asked often they currently used ecstasy. 
Response options were: every day, once a week, about once a month, every few months, 
once or twice a year, less often and finally, don’t currently use. Participants were 
categorized according to their ecstasy use status across three categories: ‘current’ use (use 
every day through to once or twice a year or less often), not current use (former use or 







ecstasy naive (never tried ecstasy). 
 Two dichotomous ecstasy use variables were created from this information: (1) 
current use (1) versus non use (0; including former use and never used) and (2) “ecstasy 
naive” (1) versus current or past use (0). The former variable was ‘time-varying’; that is, 
could take on either value at Wave 2 or 3. This variable thus captured changes in ecstasy 
use. The latter variable was time-invariant; that is, it identified participants who had not 
used ecstasy at either wave, and took on the same value at both waves of data for the 
same individual. These two variables were simultaneously included in longitudinal 
models. The latter controlled for the variability in depression that was due to the (known) 
lower rates of depression amongst people who have never used illicit drugs. 
Consequently, the remaining effect of ecstasy use can be interpreted as the association 
between current ecstasy use and depression over the two waves of data over and above 
that association due to drug naivety.  
Brief Patient Health Questionnaire (BPHQ) 
 The Brief Patient Health Questionnaire (BPHQ; Spitzer et al. 1999) was 
completed. This provides a provisional diagnosis or syndrome: to make a formal 
diagnosis other causes must be ruled out (e.g. bereavement, history of manic episodes, 
physical illness, medication, drug use).  A dichotomous variable was created comprised 
of no depression/subsyndromal depression (< two symptoms of the depression scale 
reported as ‘more than half days’ including item 1 or 2) versus major/other depression 
(cutoff score of 10 or more for mild depression and five of the nine depression items 
reported as ‘half days or more’ or ‘on several days’ for the suicidal ideation variable for 
moderate depression). 
Goldberg depression scale 
 The Goldberg depression scaled (Goldberg et al. 1988) is comprised of a 
nine-item scale measuring depressive symptoms. Items assess experience of a particular 







response options were dichotomous (yes/no), providing a range of 0-9 with higher scores 
indicative of more symptoms. 
Covariates 
Binary drug use variables were created to categorize participants at each wave as 
using/not using cannabis and cigarettes.  A binary meth/amphetamine variable was 
created for ever used meth/amphetamines for non-medical purposes. An error in the skip 
programming at Wave 3 resulted in those who previously reported prior use of both 
ecstasy and meth/amphetamines, but no ecstasy use in the last 12 months, not being asked 
for frequency data on their meth/amphetamines use. A binary alcohol use variable was 
also created to distinguish hazardous/non-hazardous drinkers at each wave according to 
responses on the Alcohol Use Disorders Identification Test (AUDIT; Saunders et al. 
1993) using the recommended cut-off score of >8 to indicate hazardous alcohol 
consumption (Conigrave et al. 1995). At Wave 3, the question used to assess heavy 
episodic drinking was revised from 6 or more drinks to 5 or more standard drinks for 
females and 7 or more for males, as consistent with Australian drinking guidelines at the 
time of Wave 3 interview (National Health and Medical Research Council 2001).  
Socio-demographic variables included sex, marital status (married versus 
separated/never married/divorced/widowed), employment status (full-time/ part-time 
versus unemployed/not in the labor force), highest level of education (higher school 
certificate or less, post-school qualification, tertiary educated) and whether experienced 
financial problems in the past year (often/sometimes versus no). 
Psychosocial measures included in analyses were positive social support from 
friends (range 0–6) and negative interaction with friends (range 0-9; Schuster et al. 1990), 
total number of lifetime traumas (as assessed by items from the Composite International 
Diagnostic Interview (World Health Organisation 1994) and number of adverse 
childhood events (Wave 1 only; Rosenman and Rodgers 2004).  
Statistical procedures 







‘mixed models’) were used to investigate the associations between ecstasy use and 
measures of depression over time. This method was chosen over commonly used 
population-averaged, regression techniques because MLM can be used to simultaneously 
model and thus ‘separate out’ differences in depression between people over time (“Level 
2”), as well as within-person changes to depression across occasions of measurement 
(“Level 1”).  Differences between individuals are estimated using ‘time-invariant’ or 
‘fixed’ effects that do not change across measurement occasions (e.g., “ecstasy naive”). 
Changes within individuals over time are estimated using time-varying effects; that is, 
variables that can change value at each occasion of measurement (Singer and Willett 
2003; e.g., current ecstasy use). This feature of MLM was considered a priority in the 
current study given the potentially different associations between depression and the 
‘types’ or groups of people that do or do not ever use ecstasy versus the association 
between changes in ecstasy use. Another considerable advantage of MLM for 
longitudinal data is the ability to include all available data from any wave in the model 
(Kwok et al. 2008); that is, it is not reliant to complete cases or use listwise deletion 
 MLM also accounts for interdependencies in the data due to similarities (i.e., 
repeated measures) in the same individuals’ responses across waves. Such 
interdependency is typically accounted for by specifying a random intercept for each 
person (Level 2) in the sample. This is the method used here. 
 Linear MLMs were used to examine continuous depression scores over time 
according to ecstasy use. Logistic MLMs were used to examine the odds of depression 
status (major/other depression versus no depression/subsyndromal depression) over time. 
These models were conducted in STATA Version 11.0 with the “xtmixed” and 
“xtmelogit” programs respectively. These programs use an expectation-maximization 
(EM) algorithm to produce maximum-likelihood estimates of model parameters. 
 
RESULTS 
Current study sample characteristics 







was a predominantly educated sample, with 44% having completed tertiary studies by 
Wave 2. Participants reported a mean 2.8 depressive symptoms in the prior 4 weeks to 
interview, with 11% meeting the criteria for major/other depression. Results for substance 
use variables demonstrate that while the majority of participants had tried cannabis and 
around a third had tried ecstasy, substance use in the sample was quite moderate in terms 
of frequency of use. Less than 10% used cannabis every month or more and close to 15% 
reported being a current ecstasy user at Wave 2, with smaller numbers of users for 
meth/amphetamine use and a decline in substance use at Wave 3. 
Changes in ecstasy use over 4 years 
 Table 2 presents a summary of participant numbers by ecstasy use status at each 
wave. At Wave 3, 30 participants who had not reported ecstasy use at Wave 2 reported 
trying the drug at an age prior to Wave 2 and these cases were added to the ‘not current 
user’ group.  There appeared to be an overall decline in use across waves. For example, 
of the 316 current ecstasy users at Wave 2, 46% (n = 145) reported not currently using 
the drug at Wave 3 and a further 10% (n = 32) reported a decline in frequency of use 
from every month or more at Wave 2 to less often at Wave 3. In terms of increases in use 
over time, 51 participants who were ecstasy naive at Wave 2 reported use by Wave 3 (41 
had tried ecstasy between waves and 10 were current users by Wave 3). An additional 34 
participants ‘not currently using’ at Wave 2 reported current ecstasy use 4 years later and 
6 participants had increased their use over time (move from infrequent to use of the drug 
monthly or more). 
Ecstasy use and Goldberg depression  
 Table 3 shows the results of the MLM for Goldberg depression scores over the 
two waves. Results for Model 1 showed a decline in depressive symptoms across time for 
the overall sample. The (time-varying) effect of current ecstasy use was significant 
indicating that participants had greater depressive symptoms when using compared to not 
using the drug. However, adjustment for ecstasy naivety (Model 2) reduced the 







non-significant. This indicates that the effect of ecstasy use was somewhat attributable to 
differences between people who have never used ecstasy across the 4 years, specifically, 
the lower depression levels of participants who never tried this drug. 
 The inclusion of socio-demographics (Model 3) and psychosocial characteristics 
(Model 4) produced a small suppressor effect on the current ecstasy use variable (that is, 
this ecstasy variable became more significant when the variability in depression due to 
these characteristics was accounted for). The final model (Model 5) included other 
substance use variables and the effect of current ecstasy use was again non-significant. 
Results for this final model showed that greater depressive symptoms were associated 
with being female, experiencing financial problems, less education, being 
unemployed/not in the labor force, a greater number of lifetime traumas and childhood 
adversities, more negative support and less positive support from friends and being a 
current smoker. Perhaps unexpectedly, no other substance use variable 
(hazardous/harmful alcohol use and use of cannabis or meth/amphetamines, in addition to 
ecstasy use) was associated with a change in depressive symptoms over time. 
 For exploratory purposes, we graphed the predicted depression scores from the 
final model by ecstasy use/non-use using average or modal values on the predictors 
(Figure 1). As shown, there was a general decline in symptoms across the two waves, 








Fig. 1. Predicted Goldberg depression scores based on final MLM by ecstasy use/non-use 
across the two waves using average/modal predictors. 
Ecstasy use and BPHQ 
 Table 4 shows the results of the MLM for the odds of major/other depression, as 
assessed by the BPHQ, over two waves of PATH data. There was no effect of current 
ecstasy use across waves on the odds of having depression (Model 1) nor were there 
differences in the odds of depression between ecstasy naive and other participants (Model 
2). The final model (Model 5) demonstrated that the odds of having depression were 
greater when participants were female, unmarried, experiencing financial problems, less 
education (relative to those who were tertiary educated), unemployed/not in the labor 
force, had experienced more lifetime traumas and had less positive and more negative 
interaction with friends. No form of current substance use was associated with the odds of 








 The current study aimed to determine if change in ecstasy use status was 
associated with a change in mental health, as assessed by self-reported depressive 
symptoms and probable depression. Among this general community sample variation in 
ecstasy use over time was not associated with changes to the odds of having major/other 
depression, as measured by the BPHQ. Findings demonstrated that participants had more 
depressive symptoms, as assessed by the Goldberg depression scale, when using the drug 
compared to not using. However, this was largely accounted for by differences in 
depression between people who had and had not ever used ecstasy. A general decline in 
symptoms was noted for the sample across time, with a greater decline in symptoms 
among those who stopped using the drug compared to those who continued using. 
Unsurprisingly, given the age of participants, a decline in ecstasy use across the two 
waves was found. 
 The consideration of other factors, such as demographics and psychosocial 
characteristics in the MLM models showed that these variables emerged as more 
important in the prediction of depressive symptoms and probable depression. Factors 
associated with higher odds of depression and more depressive measures included 
experiencing financial problems, unemployment, lower education, more lifetime traumas, 
more positive and less negative interaction with friends. Of interest, no other substance 
use variable with the exception of smoking cigarettes for Goldberg depression was 
significant in the final models. It has previously been reported that smoking is a causal 
factor in depression (Boden et al. 2010) thereby highlighting the importance of 
controlling for other factors when examining these associations.  
 As noted, inclusion of sociodemographic factors, such as education and 
employment and psychosocial characteristics, such as childhood adversity produced a 
small suppressor effect on the ecstasy use variable for Goldberg depression. That is, the 
effect of ecstasy use became more significant with the inclusion of these variables. 







may reflect the atypical drug use profile of ecstasy users given that higher employment, 
more education, support from friends and less childhood adversity/lifetime trauma was 
associated with fewer depressive symptoms. 
 Results presented here are broadly consistent with the bulk of research that has 
examined ecstasy use and depression over time. For example, Falck et al. (2008) reported 
an overall decline in depressive symptoms over time for both continuous and abstention 
users and others reported no effect of ecstasy use over time (Daumann et al. 2004; de Win 
et al. 2007; Thomasius et al. 2006).  However, unlike Martin-Santos et al. (2010) where it 
was found that ecstasy users had a higher incidence of primary mood disorder over a 3 
year period, no association of ecstasy use with probable depression was detected here. It 
is important to note the relatively low level of ecstasy and other drug use in the current 
community sample which may have contributed to this difference. We did, however, 
demonstrate an overall decline in symptoms across the sample by ecstasy use/non-use 
except for those who moved from not using the drug to using at Wave 3. With a heavier 
using sample the result for ecstasy use may have been significant, despite the identified 
importance of controlling for other factors.   
 Similar to other studies (George et al. 2010; Scott et al. 2010) it emerged that 
other factors were more important in the prediction of depression than ecstasy use. The 
benefit of considering both demographics and psychosocial characteristics which are 
often excluded in the literature when examining ecstasy and mental health was apparent. 
However, unlike these investigations, we did not detect a significant effect of other drug 
use with the exception of current smoking for Goldberg depression. This finding, 
particularly for cannabis use, was unexpected. It may again reflect the relatively low level 
of drug use among the current sample or the inclusion of binary drug use variables in the 
longitudinal models. 
 The strengths of the current study include use of a population-based sample as 
opposed to the typical purposive/snowball samples and examination of participants over 4 
years. Additionally, use of multiple measures of depression (both self-report and probable 







associated with both ecstasy use and mental health. An important contribution is that we 
showed the effect of current ecstasy use was largely driven by differences between 
participants who had or had never used the drug. If this had not been considered one 
could erroneously conclude that it was ecstasy use per se which was linked to changes in 
depression.  
 The epidemiological nature of the study makes an important contribution. 
However, information regarding ecstasy use was limited. Ecstasy dosage was unknown 
and analyses were limited to current use/non-use of ecstasy and other drugs. The effect of 
former use was limited by the lack of knowledge regarding former drug use. Those 
reporting they ‘don’t currently use’ and those who had ever tried the drug, but not used in 
the prior year, were included in the group of ‘not current users’.  Unlike most 
purposive investigations, the current sample had a relatively low level of ecstasy and 
other drug use. Small samples of ecstasy users were a concern/limitation, and an 
unavoidable outcome of using community-based samples. We still, however, consider our 
sampling method to be a significant strength of the study because it addresses this 
limitation from other studies. Also, the relatively small sample size makes for a 
‘conservative’ estimate (i.e., if anything, the effect is underestimated, rather than inflated, 
which may be the case in purposively-recruited samples). 
It would be premature to conclude that ecstasy use is not related to the 
development of long-term depressive symptoms, on the basis of findings presented here. 
It is possible that different results could have been obtained among a heavier using 
sample. Additionally, early onset of ecstasy use and other risk factors for depression were 
not examined here. As per other studies among human samples, the purity and presents of 
adulterants in the ecstasy was unknown. Street ‘ecstasy’ may contain little or no MDMA 
and instead maybe a mixture of meth/amphetamines, ketamine and other substances 
(Australian Crime Commission 2012).  The narrow age bracket and geographical 
distribution of the sample limit generalization of these findings, and alternative indicators 
of ecstasy use (such as dosage) which were not assessed may have altered results.  







when examining the effect of ecstasy and other drug use longitudinally. Examining 
longitudinal effects, particularly among population-based samples, with detailed drug use 
information should account for differences between people who never use this drug rather 
than changes in ecstasy use per se. The former effect may confound or be an artefact of 
these differences.  Results presented here are broadly consistent with the existing 
longitudinal literature which has generally failed to identify a specific effect of ecstasy 
use on mental health over time. Still, the continual assessment of users/non-users beyond 
a 4 year period with heavier using samples would also enable the investigation of 
threshold effects and the possibility of reversal of damage among former users of the 
drug to be better understood. 
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Table 1 Characteristics of the sample across the two waves  
 
 
 Wave 2 

















Highest education level 
  ≤ Higher school certificate 
  Post-school qualification 













Married  % (N) 26.4 (561) 45.6 (902) 
Currently employed % (N) 88.6 (1,885) 90.2 (1,785) 
Financial problems in past 
year 
% (N) 23.0 (489) 18.6 (367) 
Psychosocial variables 








Number of adverse childhood 







Positive support from friends M (SD) 5.07 (1.20) 5.06 (1.19) 
Negative interaction with 
friends 
M (SD) 2.98 (1.74) 2.79 (1.69) 
Depression    
Goldberg depression score M (SD) 2.83 (2.48) 2.63 (2.44) 
Major/other depression (Brief 










Substance use variables 
Ecstasy use 
  Never used 
  Former use
b 
  Infrequent use
c
 


























  Never used 
  Former use
b 
  Infrequent use
c
 





















  Never used 
  Former use
b 
  Infrequent use
c
 
















Hazardous/harmful drinker % (N) 28.3 (603) 24.2 (478) 
Current smoker % (N) 27.4 (583) 20.9 (413) 
a
Sample sizes differ due to missing data for some variables. 
b
Includes participants who have tried the substance, but not used in the past year and those 
who used the substance in the past year, but when asked how often they were currently using 
reported ‘don’t currently use’ 
c
Refers to less than monthly use. 
d
Data not presented since those who used meth/amphetamines and ecstasy, but no ecstasy in 








Table 2 Participant numbers at each wave by ecstasy status 
 Wave 2  














































Total 1,278 354 278 1,910 
a
Includes participants who have tried ecstasy, but not used in the past year and those who 
used ecstasy in the past year, but when asked how often they were currently using reported 
‘don’t currently use’. 
b
Includes participants who have used ecstasy in the past year and when asked how often they 
were currently using the drug responded either every day, once a week, about once a month, 



























Time -0.14 (.06)* -0.15 (.06)* -0.04 (.06) -0.14 (.06)* -0.11 (.06) 
Current ecstasy use 0.30 (.12)* 0.20 (.14) 0.24 (.13) 0.29 (.13)* 0.19 (.14) 
Ecstasy naive  
 
0.19 (.11) 0.11 (.11)* 0.02 (.10) -0.05 (.12) 
Gender (female)   0.56 (.09)* 0.80 (.09)*** 0.81 (.09)*** 
Marital status (married)   -0.19 (.08)* -0.10 (.08) -0.07 (.08) 
Financial problems   1.02 (.09)*** 0.70 (.09)*** 0.67 (.09)*** 
 Employment status (employed)  
  
  -0.49 (.12)*** -0.44 (.12)*** -0.44 (.12)*** 
 Highest education level
a
  
  Post-school qualification 













Number of lifetime traumas    0.16 (.03)*** 0.14 (.03)*** 
 Total number of childhood adversities    0.09 (.02)*** 0.09 (.02)*** 
 Positive support from friends    -0.38 (.03)*** -0.38 (.03)*** 
 Negative support from friends    0.19 (.02)*** 0.18 (.02)*** 
 Current smoker     0.37 (.10)*** 







 Current cannabis use     0.07 (.11) 
 Have used meth/amphetamines     -0.02 (.12) 
a
Reference group is higher school certificate or less. 




























OR (95% CI) 
 
Time 0.79 (0.63-1.00) 
 
0.79 (0.62-1.00)* 0.99 (0.77-1.26) 0.85 (0.66-1.11) 0.87 (0.67-1.13) 
Current ecstasy use 1.24 (0.83-1.87) 1.11 (0.70-1.77) 1.00 (0.63-1.58) 1.04 (0.66-1.65) 1.04 (0.64-1.69) 
Ecstasy naive  
 
1.18 (0.83-1.66) 0.96 (0.69-1.35) 0.89 (0.64-1.24) 0.90 (0.61-1.33) 
Gender (female)   0.94 (0.71-1.25) 1.34 (1.00-1.79) 1.38 (1.03-1.85)* 
Marital status (married)   0.49 (0.36-0.67)*** 0.56 (0.41-0.76)*** 0.57 (0.42-0.78)*** 
Financial problems   3.42 (2.52-4.64)*** 2.07 (1.52-2.80)*** 2.03 (1.50-2.75)*** 




  Post-school qualification 
  Tertiary educated 
 
 









Number of lifetime traumas    1.17 (1.07-1.26)*** 1.17 (1.08-1.26)*** 
Total number of childhood 
adversities 
   1.06 (0.99-1.12) 1.05 (0.99-1.12) 
Positive support from friends    0.59 (0.53-0.65)*** 0.59 (0.53-0.65)*** 
Negative support from friends    1.19 (1.10-1.28)*** 1.17 (1.09-1.26)*** 



























OR (95% CI) 
 
Hazardous/harmful alcohol use     1.06 (0.77-1.45) 
Current cannabis use     1.17 (0.79-1.71) 
Ever used meth/amphetamines     0.86 (0.57-1.30) 
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ .001. 
a
Reference group is higher school certificate or less. 
